Roy van der Meel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3449137/publications.pdf

Version: 2024-02-01

46 papers	6,670 citations	159358 30 h-index	214527 47 g-index
48 all docs	48 docs citations	48 times ranked	8650 citing authors

#	Article	IF	Citations
1	Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. Journal of Controlled Release, 2022, 349, 174-183.	4.8	10
2	A modular approach toward producing nanotherapeutics targeting the innate immune system. Science Advances, 2021, 7, .	4.7	20
3	Prosaposin mediates inflammation in atherosclerosis. Science Translational Medicine, 2021, 13, .	5.8	42
4	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	15.6	578
5	Nanoengineering Apolipoprotein A1â€Based Immunotherapeutics. Advanced Therapeutics, 2021, 4, 2100083.	1.6	8
6	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small, 2021, 17, e2103025.	5.2	29
7	Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach. Langmuir, 2021, 37, 1120-1128.	1.6	50
8	Roadmap on nanomedicine. Nanotechnology, 2021, 32, 012001.	1.3	17
9	Nuclear imaging approaches facilitating nanomedicine translation. Advanced Drug Delivery Reviews, 2020, 154-155, 123-141.	6.6	41
10	Dexamethasone nanomedicines for COVID-19. Nature Nanotechnology, 2020, 15, 622-624.	15.6	138
11	Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica, 2020, 41, 954-958.	2.8	33
12	Nanotechnology for organ-tunable gene editing. Nature Nanotechnology, 2020, 15, 253-255.	15.6	16
13	The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics, 2020, 10, 7921-7924.	4.6	459
14	Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 2020, 159, 344-363.	6.6	187
15	Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency. Blood, 2020, 136, 2946-2954.	0.6	17
16	Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Accounts of Chemical Research, 2019, 52, 2435-2444.	7.6	270
17	Smart cancer nanomedicine. Nature Nanotechnology, 2019, 14, 1007-1017.	15.6	776
18	Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale, 2019, 11, 9023-9031.	2.8	85

#	Article	IF	Citations
19	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 2019, 14, 1084-1087.	15.6	814
20	Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. Nucleic Acid Therapeutics, 2018, 28, 146-157.	2.0	335
21	On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano, 2018, 12, 4787-4795.	7.3	319
22	Stateâ€ofâ€theâ€Art Design and Rapidâ€Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery. Small Methods, 2018, 2, 1700375.	4.6	165
23	Translating nanomedicines: Thinking beyond materials? A young investigator's reply to â€˜The Novelty Bubbleâ€™. Journal of Controlled Release, 2018, 290, 138-140.	4.8	12
24	In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System. Molecular Pharmaceutics, 2017, 14, 1681-1690.	2.3	18
25	Cancer nanomedicines: oversold or underappreciated?. Expert Opinion on Drug Delivery, 2017, 14, 1-5.	2.4	107
26	Cetuximab treatment alters the content of extracellular vesicles released from tumor cells. Nanomedicine, 2016, 11, 881-890.	1.7	20
27	The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. Molecular Therapy, 2016, 24, 2100-2108.	3.7	38
28	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. Journal of Controlled Release, 2016, 224, 77-85.	4.8	402
29	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. Fundamental Biomedical Technologies, 2016, , 163-200.	0.2	16
30	An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs. European Journal of Pharmaceutical Sciences, 2015, 74, 103-117.	1.9	40
31	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Îâ€“Î Stacking Stabilized Polymeric Micelles. ACS Nano, 2015, 9, 3740-3752.	7.3	185
32	Capillary electrophoresis-based assessment of nanobody affinity and purity. Analytica Chimica Acta, 2014, 818, 1-6.	2.6	17
33	Extracellular vesicles as drug delivery systems: Lessons from the liposome field. Journal of Controlled Release, 2014, 195, 72-85.	4.8	372
34	Toward routine detection of extracellular vesicles in clinical samples. International Journal of Laboratory Hematology, 2014, 36, 244-253.	0.7	56
35	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	2.3	26
36	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 2013, 65, 1284-1298.	6.6	338

#	Article	IF	Citations
37	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Journal of Controlled Release, 2013, 165, 110-118.	4.8	88
38	Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. Journal of Controlled Release, 2012, 160, 211-216.	4.8	33
39	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	4.8	83
40	Nanobody â€" Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. Journal of Controlled Release, 2011, 151, 183-192.	4.8	94
41	Reprint of "Nanobody â€" Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". Journal of Controlled Release, 2011, 153, 93-102.	4.8	29
42	The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discovery Today, 2011, 16, 219-228.	3.2	65
43	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. Angiogenesis, 2011, 14, 457-466.	3.7	37
44	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of Controlled Release, 2010, 145, 165-175.	4.8	117
45	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discovery Today, 2010, 15, 102-114.	3.2	45
46	Controlling Cardiomyocyte Survival. Novartis Foundation Symposium, 2008, , 41-57.	1.2	12